secwatch.observer — SEC 8-K summary
======================================

Issuer:     Acurx Pharmaceuticals, Inc. (ACXP)
CIK:        0001736243
Form:       8-K
Filed at:   2022-07-25T23:59:59+00:00
Accession:  0001104659-22-082266
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 2.02, 3.02, 5.05, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Acurx Pharmaceuticals raises $4.225M in registered direct offering; reports $9.1M cash
--------------------------------------------------------------------------------

- Gross proceeds of ~$4.225M from sale of 1,289,980 shares/pre-funded warrants at $3.25 (institutional) and $3.80 (executives).
- Concurrent private placement of Series A and B warrants to purchase up to 1,289,980 shares each; exercisable starting 6 months.
- Preliminary cash and equivalents $9.1M as of June 30, 2022 (unaudited).
- Board granted one-time waiver of Insider Trading Policy to let CEO, Executive Chairman, and director participate in the offering.
- Net proceeds for general corporate purposes; closing expected July 27, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1736243/000110465922082266/0001104659-22-082266-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1736243/000110465922082266/tm2221625d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-082266

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer